01:50 AM EDT, 08/17/2026 (MT Newswires) -- Belgium-listed immunology company Argenx (ARGX.BR) said Monday that a phase 3 Alkivia trial evaluating its autoimmune myositis treatment efgartigimod met its primary endpoint. In the combined population of patients with immune-mediated necrotizing myopathy and dermatomyositis, those receiving efgartigimod showed a 15.4-point greater mean total improvement score at week 52 compared with placebo. The study also met its primary endpoint in the IMNM subgroup, while patients with dermatomyositis showed a similar magnitude of improvement that did not reach statistical significance.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.